NCIC Clinical Trials Group Abstracts to be Presented at the ASCO 2011 Annual Meeting
McCormick Place
June 3-7, Chicago, Illinois
BR.10 – Stefan Michiels
Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. (Abstract 7004)
Oral Abstract Session – Lung Cancer – Local Regional and Adjuvant Therapy/Small Cell
Tuesday: 8:00 AM – 11:00 AM, Location: Arie Crown Theatre
Presentation Time: 9:45 AM – 10:00 AM
Chair and/or Co-chairs: Tom Stinchcombe, MD & Wilfried E. Eberhardt, MD
BR.21 – John F. Hilton
An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib.
Poster Discussion Session –Lung Cancer – Metastatic/Non-small Cell
Monday: 2:00 PM - 6:00 PM (Location: E450a)
Discussion: Monday: 5:00 PM 6:00 PM (Location: Hall D2)
Board No. 12 Abstract No. 7523
CO.17 – Elena Elimova
Cetuximab (CET)-related hypersensitivity reactions (HSRs): An analysis of timing, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial.
General Poster Session – Gastrointestinal (Colorectal) Cancer
Saturday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 20H Abstract No. 3624
CO.17 – Christopher J. O’Callaghan
The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17.
General Poster Session – Gastrointestinal (Colorectal) Cancer
Saturday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 16D Abstract No. 3588
CO.17 – Guy A. Van Hazel
Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study.
General Poster Session – Gastrointestinal (Colorectal) Cancer
Saturday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 18B Abstract No. 3602
CO.17 – Michael M. Vickers
The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG / AGITG CO.17.
General Poster Session – Gastrointestinal (Colorectal) Cancer
Saturday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 18A Abstract No. 3601
CO.20 – Jeremy D. Shapiro
A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.
Trials in Progress Poster Session
Monday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 44A Abstract No. TPS163
IND.192 – Helen Mackay
Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.
Poster Discussion Session –Gynecologic Cancer
Friday: 2:00 PM - 6:00 PM (Location: E450a)
Discussion: Friday: 5:00 PM 6:00 PM (Location: E354b)
Board No. 2 Abstract No. 5013
LY.11 – Patrick J. Stiff
Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP±R for eight cycles to CHOP±R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin's lymphoma (NHL). (Abstract 8001)
Oral Abstract Session – Lymphoma
Saturday: 1:30 PM – 4:00 PM, Location: S406
Presentation Time: 1:45 PM – 2:00 PM
Chair and/or Co-chairs: Myron S. Czuczman, MD & Gilles A. Salles, MD, PhD
MA.5 – Maggie Chon U. Cheang
The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial.
Poster Discussion Session – Breast Cancer – Triple-negative/Cytotoxics/ Local Therapy
Saturday: 2:00 PM – 6:00 PM (Location: E450b)
Discussion: Saturday; 5:00 PM to 6:00 PM (Location: Hall B1)
Board No. 22 Abstract No. 1032
Dr. Cheang’s abstract was selected for the Novartis Oncology Young Canadian Investigator Awards (NOYCIA). Presentations will be made at a dinner on Sunday June 5th, at 6:30 pm at the Trump International Hotel.
MA.12 – Mark Basik
Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer.
General Poster Session – Breast Cancer – HER2/ER
Monday: 1:00 PM – 5:00 PM (Location: Hall A)
Board No. 4B Abstract No. 560
MA.12-MA.14-MA.21-MA.27-MA.5 – Rinat Yerushalmi
Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer.
Poster Discussion Session – Breast Cancer – HER2/ER
Tuesday: 8:00 AM – 12:00 PM (Location: E450a)
Discussion: Tuesday; 11:30 AM to 12:30 PM (Location: Arie Crown Theater)
Board No. 2 Abstract No. 513
MA.14 – Adriana Aguilar-Mahecha
Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.
General Poster Session – Breast Cancer – HER2/ER
Monday: 1:00 PM – 5:00 PM (Location: Hall A)
Board No. 6C Abstract No. 577
MA.20 – Timothy J. Whelan
Highlighted in ASCO Official Press Program and selected for Best of ASCO
NCIC-CTG MA.20: An Intergroup Trial of Regional Nodal Irradiation in Early Breast Cancer
(Abstract LBA1003)
Oral Abstract Session – Breast Cancer –Triple-negative/Cytotoxics/Local Therapy
Monday: 9:30 AM – 12:30 PM, Location: Hall B1
Presentation Time: 9:45 AM – 10:00 AM
Chair and/or Co-chairs: Lisa Yee, MD, and Melinda L. Telli, MD
MA.27B – Dawn L. Hershman
Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study.
Poster Discussion Session – Breast Cancer – HER2/ER
Tuesday: 8:00 AM – 12:00 PM (Location: E450a)
Discussion: Tuesday; 11:30 AM to 12:30 PM (Location: Arie Crown Theater)
Board No. 7 Abstract No. 518
MA.27 – Vered Stearns
Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial.
Poster Discussion Session – Breast Cancer – HER2/ER
Tuesday: 8:00 AM – 12:00 PM (Location: E450a)
Discussion: Tuesday: 11:30 AM to 12:30 PM (Location: Arie Crown Theater)
Board No. 14 Abstract No. 525
MA.31 – Wendy Parulekar
Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG )MA.31/GSK EGF 108919).
Trials in Progress Poster Session
Monday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 37B Abstract No. TPS108
MA.32 – Wendy Parulekar
Aphase III randomizedtrial of metformin versus placebo onrecurrence andsurvivalinearly stagebreastcancer (BC) (NCIC Clinical Trials Group MA.32).
Trials in Progress Poster Session
Monday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 36E Abstract No. TPS103
MAP.3 – Paul E. Goss
Highlighted in ASCO Official Press Program and selected for Best of ASCO
Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3 - A randomized placebo-controlled clinical trial. (Abstract LBA504)
Oral Abstract Session – Breast Cancer – HER2/ER
Sunday: 9:00 AM – 12:00 PM, Location: Hall B1
Presentation Time: 9:00 AM – 9:15 AM
Chair and/or Co-chairs: Harold J. Burstein, MD, PhD & Rebecca A. Dent, MD, FRCPC
OV.15 – Christian Kurzeder
The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5.
General Poster Session – Gynecologic Cancer
Sunday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 20D Abstract No. 5088
OV.17 – Sven Mahner
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial.
General Poster Session – Gynecologic Cancer
Sunday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 16G Abstract No. 5059
OV.17 – Christian Marth
Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.
General Poster Session – Gynecologic Cancer
Sunday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 15H Abstract No. 5052
OV.17 – Benoit You
Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study.
General Poster Session – Gynecologic Cancer
Sunday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 17E Abstract No. 5065
OV.19 – Gunnar Kristensen
Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. (Abstract LBA5006)
Oral Abstract Session – Gynecologic Cancer
Saturday: 3:00 PM – 6:00 PM, Location: E354a
Presentation Time: 4:00 PM – 4:15 PM
Chair and/or Co-chairs: Ronald J. Buckanovich, MD & Gottfried E. Konecny, MD
PR.7 – Juanita M. Crook - Selected for Best of ASCO
A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/ 01/013). (Abstract 4514)
Oral Abstract Session – Genitourinary Cancer (Prostate)
Monday: 1:00 PM – 4:00 PM, Location: Hall D1
Presentation Time: 2:30 PM – 2:45 PM
Chair and/or Co-chairs: Joshi J. Alumkal, MD, and Ajjai S. Alva, MBBS, MS
Other – Judy-Anne W. Chapman
Comparison of innovative estimation of efficacy to standard using the ACCENT database.
General Poster Session – Gastrointestinal (Colorectal) Cancer
Saturday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 19H Abstract No. 3616
Other – Melanie Walker
Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study.
General Poster Session – Health Services Research
Saturday: 8:00 AM – 12:00 PM (Location: Hall A)
Board No. 51G Abstract No. 6131
3